 Connection
David Fox to Antirheumatic Agents
This is a "connection" page, showing publications David Fox has written about Antirheumatic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.132 |
|
|
|
-
Wallace BI, Lin P, Kamdar N, Noureldin M, Hayward R, Fox DA, Curtis JR, Saag KG, Waljee AK. Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. Semin Arthritis Rheum. 2020 04; 50(2):228-236.
Score: 0.033
-
Ohara RA, Edhayan G, Rasmussen SM, Isozaki T, Remmer HA, Lanigan TM, Campbell PL, Urquhart AG, Lawton JN, Chung KC, Fox DA, Ruth JH. Citrullinated Inhibitor of DNA Binding 1 Is a Novel Autoantigen in Rheumatoid Arthritis. Arthritis Rheumatol. 2019 08; 71(8):1241-1251.
Score: 0.032
-
Fechtner S, Fox DA, Ahmed S. Transforming growth factor ß activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology (Oxford). 2017 07 01; 56(7):1060-1068.
Score: 0.028
-
Cottier KE, Fogle EM, Fox DA, Ahmed S. Noxa in rheumatic diseases: present understanding and future impact. Rheumatology (Oxford). 2014 Sep; 53(9):1539-46.
Score: 0.022
-
Gizinski AM, Fox DA, Sarkar S. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract Res Clin Rheumatol. 2010 Aug; 24(4):463-77.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|